Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 254

Sort by

Sort Order Select

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Moshe Yair Levy, MD, Jae H. Park, MD, Farhad Ravandi, MD, Alexander E. Perl, MD, John M. Pagel, MD PhD, B. Douglas Smith, MD, Elihu H. Estey, MD, Hagop Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4050.

https://doi.org/10.1182/blood.V128.22.4050.4050

Published: 2016

Journal Articles

Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML)

Michael W. Schuster, MD, Mikkael A. Sekeres, MD MS, Erick Gamelin, MD PhD, Erik Rasmussen, MS, Gloria Juan, PhD, Abraham Anderson, PhD, Vincent Chow, PhD, Greg Friberg, MD, Florian D. Vogl, MD PhD, Hagop Kantarjian, MD

Blood (2015) 126 (23): 4929.

https://doi.org/10.1182/blood.V126.23.4929.4929

Published: 2015

Journal Articles

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H. Park, MD, B. Douglas Smith, MD, Moshe Yair Levy, MD, Elihu H. Estey, MD, Alexander E. Perl, MD, Hagop Kantarjian, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2015) 126 (23): 3794.

https://doi.org/10.1182/blood.V126.23.3794.3794

Published: 2015

Journal Articles

Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia

Hagop Kantarjian, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Courtney DiNardo, MD, Naval Daver, MD, Gautam Borthakur, MD, Nitin Jain, MD, Jane Waukau, RN, BSN, Monica Kwari, RN, BSN, Barry Douglas Anderson, MD PhD, Kenzo Iizuka, Cheng Jin, MD PhD, William Plunkett, PhD

Blood (2015) 126 (23): 3804.

https://doi.org/10.1182/blood.V126.23.3804.3804

Published: 2015

Journal Articles

Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure

Punit L Jain, MD, Koji Sasaki, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Prithviraj Bose, MD, Naval Daver, MD, Tapan Kadia, MD, Srdan Verstovsek, MD, Marina Konopleva, MD PhD, Nitin Jain, MD, Guillermo Bravo Montalban, MD, Sherry Pierce, BSN, BA, Elias Jabbour

Blood (2015) 126 (23): 3718.

https://doi.org/10.1182/blood.V126.23.3718.3718

Published: 2015

Journal Articles

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Tapan Kadia, MD, Farhad Ravandi, MD, Naval Daver, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Elias Jabbour, Steven M. Kornblau, MD, Srdan Verstovsek, MD, William Wierda, MD PhD, Jan A Burger, MD PhD, Zeev Estrov, MD, Courtney DiNardo, MD, Xiao Qin Dong, Naveen Pemmaraju, MD, Maro Ohanian, DO, Koichi Takahashi, MD, Stephany Hendrickson, RN, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 4779.

https://doi.org/10.1182/blood.V126.23.4779.4779

Published: 2015

Journal Articles

The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies

Vikas Gupta, MD FRCP, FRCPath, Claire N. Harrison, Elizabeth O. Hexner, MD, Haifa Kathrin Al-Ali, MD, Lynda Foltz, MD FRCP, Michael Montgomery, MD, Wei Peng, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Hagop Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2015) 126 (23): 1604.

https://doi.org/10.1182/blood.V126.23.1604.1604

Published: 2015

Journal Articles

Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Jonathan E. Brammer, MD, Rima M Saliba, PhD, Jeffrey L. Jorgensen, MD PhD, Celina Ledesma, Gabriela Rondon, MD, Michelle Poon, Liang Piu Koh, William Dibb, BA, Guang Fan, MD PhD, Cynthia K Saliba, College Trainee, Sa Wang, MD, Uday R. Popat, MD, Elizabeth J. Shpall, MD, Farhad Ravandi, MD, Hagop Kantarjian, MD, Richard Thomas Maziarz, MD, Richard E. Champlin, MD, Chitra M. Hosing, MD, Partow Kebriaei, MD

Blood (2015) 126 (23): 4408.

https://doi.org/10.1182/blood.V126.23.4408.4408

Published: 2015

Journal Articles

Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI)

Mary Akosile, BA, Sherry Pierce, BSN, BA, Mark Brandt, BS, Srdan Verstovsek, MD, Gautam Borthakur, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD, William Wierda, MD PhD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan Kadia, MD, Jan A. Burger, MD PhD, Naveen Pemmaraju, MD, Elias Jabbour, Jorge E. Cortes, MD

Blood (2015) 126 (23): 1587.

https://doi.org/10.1182/blood.V126.23.1587.1587

Published: 2015

Journal Articles

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

Hagop Kantarjian, MD, Ghulam J. Mufti, MD PhD, Pierre Fenaux, MD PhD, Mikkael A. Sekeres, MD MS, Jeffrey Szer, MB BS FRACP, Uwe Platzbecker, MD, Andrea Kuendgen, MD, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, MD PhD, Janet Franklin, MD MPH, Aristoteles Giagounidis, MD

Blood (2015) 126 (23): 2863.

https://doi.org/10.1182/blood.V126.23.2863.2863

Published: 2015

Journal Articles

The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)

Amer M. Zeidan, MBBS, MHS, Mikkael A. Sekeres, MD MS, Guillermo Garcia-Manero, MD, John Barnard, Najla H Al Ali, Cassie Zimmerman, MA, Gail J. Roboz, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Elias Jabbour, MD, Hagop Kantarjian, MD, Katrina Zell, Quiqing Wang, Steven D Gore, Aziz Nazha, MD, Jaroslaw P. Maciejewski, MD PhD, Alan F. List, MD, Rami S Komrokji, MD

Blood (2014) 124 (21): 1935.

https://doi.org/10.1182/blood.V124.21.1935.1935

Published: 2014

Journal Articles

Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study

Monica Cabrero, MD, Guillermo Garcia-Manero, MD, Koji Sasaki, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Jorge E. Cortes, MD, Zach Bohannan, Victoria Sukholutsky, Farhad Ravandi, MD, Sherry Pierce, BSN, BA, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Betul Oran, MD, Richard E. Champlin, Hagop Kantarjian, MD, Elias Jabbour, MD

Blood (2014) 124 (21): 4666.

https://doi.org/10.1182/blood.V124.21.4666.4666

Published: 2014

Journal Articles

Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy

Elias Jabbour, MD, Koji Sasaki, Naval Daver, Naveen Pemmaraju, MD, Nitin Jain, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Stefan H. Faderl, MD, Susan O'Brien, MD, Jorge Cortes, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 534.

https://doi.org/10.1182/blood.V124.21.534.534

Published: 2014

Journal Articles

Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results

Neil P. Shah, MD PhD, Philippe Rousselot, MD PhD, Charles A. Schiffer, MD, Delphine Rea, MD PhD, Jorge E. Cortes, MD, Jorge Milone, MD, Hesham Mohamed, MD, Diane Healey, MS, Hagop Kantarjian, MD, Andreas Hochhaus, MD, Giuseppe Saglio, MD

Blood (2014) 124 (21): 520.

https://doi.org/10.1182/blood.V124.21.520.520

Published: 2014

Journal Articles

A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Courtney D. DiNardo, MD, Naval Daver, MD, Elias Jabbour, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Hui Yang, MD PhD, Yue Wei, William G. Wierda, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MD PhD, Jorge E. Cortes, Farhad Ravandi, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 164.

https://doi.org/10.1182/blood.V124.21.164.164

Published: 2014

Journal Articles

Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Jorge E. Cortes, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Alfonso Quintas-Cardama, MD, Farhad Ravandi, MD, Evguenia Gachimova, Zeev Estrov, MD, Elias Jabbour, MD, Susan O'Brien, MD, Hagop Kantarjian, MD

Blood (2013) 122 (21): 1483.

https://doi.org/10.1182/blood.V122.21.1483.1483

Published: 2013

Journal Articles

Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR + ) Populations In Patients With Myelodysplastic Syndrome (MDS)

Preetesh Jain, MD, DM, PhD, Hagop Kantarjian, MD, Keyur P. Patel, MD, PhD, Elias Jabbour, MD, Naval Daver, MD, Sherry Pierce, Ohad Benjamini, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Stefan H. Faderl, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2013) 122 (21): 5231.

https://doi.org/10.1182/blood.V122.21.5231.5231

Published: 2013

Journal Articles

Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.

Sairah Ahmed, MD, Rima M Saliba, Ph.D, Marcos De Lima, MD, Gabriela Rondon, MD, Partow Kebriaei, MD, Tobi DeAnn Fisher, MPAS, Elias Jabbour, MD, Julianne Chen, Hagop Kantarjian, MD, Paolo Anderlini, MD, Amin M Alousi, MD, Chitra M Hosing, MD, Borje Andersson, MD, PhD, Roy B. Jones, MD, Ph.D., Muzaffar H. Qazilbash, MD, Elizabeth J. Shpall, MD, Sergio Giralt, MD, Richard E Champlin, MD

Blood (2012) 120 (21): 3129.

https://doi.org/10.1182/blood.V120.21.3129.3129

Published: 2012

Journal Articles

Death In Complete Remission Among Patients with Acute Myeloid Leukemia: A Preventable Problem?

Gloria Mattiuzzi, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Stefan Faderl, MD, Tapan Kadia, MD, Zeev Estrov, MD, Gloria Iliescu, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD

Blood (2010) 116 (21): 2710.

https://doi.org/10.1182/blood.V116.21.2710.2710

Published: 2010

Journal Articles

Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction

Farhad Ravandi, MD, Keyur P. Patel, MD, PhD, Rajyalakshmi Luthra, PhD, Stefan Faderl, MD, Marina Konopleva, MD, PhD, Tapan Kadia, MD, Mark Brandt, Sherry Pierce, RN, BSC, Steven M. Kornblau, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2706.

https://doi.org/10.1182/blood.V116.21.2706.2706

Published: 2010

NARROW

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients (Pts) with Acute Myeloid Leukemia (AML)

Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia

Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

The Impact of Anemia on Overall Survival in Patients with Myelofibrosis Treated with Ruxolitinib: An Exploratory Analysis of the Comfort Studies

Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI)

Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study

The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)

Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study

Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy

Seven-Year (yr) Follow-up of Patients (pts) with Imatinib-Resistant or -Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Receiving Dasatinib in Study CA180-034, Final Study Results

A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR + ) Populations In Patients With Myelodysplastic Syndrome (MDS)

Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.

Death In Complete Remission Among Patients with Acute Myeloid Leukemia: A Preventable Problem?

Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only